Targeted drug trial for tough pancreatic cancer withdrawn before starting
Disease control
Terminated
This study aimed to test an experimental drug called GFH375 in people with advanced pancreatic cancer that had spread and had a specific genetic change (KRAS G12D mutation), and who had already tried other treatments. The goal was to see if the drug could shrink tumors, control t…
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC